The next evolution of
biomanufacturing
We deliver the next generation of bioprocess technologies by leveraging the strengths of process intensification and chaining
Products
We design innovative cost-
effective manufacturing solutions
scale-X™ bioreactor
Intensified fixed-bed technology for
cost-effective & scalable viral production
NevoLine™ Upstream platform
Integrated & automated solution
for intensified virus manufacturing
Publications
Leveraging small-scale parallel bioreactor systems for reliable and scalable processing design
Our Product Manager Clément Dumont explains how an innovative fixed-bed small-scale parallel system will revolutionize process design & optimization steps resulting in an increased production capacity & quality.
Download
Suspension-based viral vector production in scale-X fixed-bed bioreactor
Shake flask process transferred in a scale-X hydro fixed-bed bioreactor for Adenovirus production with HEK293 cells adapted to suspension.
Learn moreIntegrated continuous biomass estimation in fixed-bed bioreactors
Novel approach allows for real-time measurement of cell density in fixed-bed bioreactors
Learn moreOur Company
We believe in technology
-driven affordability
Our team
Successfully leading
our innovation
Our history
Redefining biomanufacturing for human health
WE ARE HIRING
Looking For Your Next Challenge ?
Newsroom
CBET becomes first US-based training partner for Univercells Technologies; partnership provides opportunities to prepare ACPHS students for successful careers in cell and gene therapy.
Read article “Albany College of Pharmacy and Health Sciences’ (ACPHS) Stack Family Center for Biopharmaceutical Education and Training (CBET) partners with Belgian-based Univercells Technologies to support bioproduction advances”
The scale-X bioreactor is an intensified and chained bioprocessing platform for viral developers and manufacturers. It multiplies product yield and reduces operational volumes per cleanroom surface area compared to traditional technology.
Read article “scale-X™ bioreactor demonstrates superior productivity for vaccines and gene therapy”